Klotho’s First Human Trial: Inside the 2026 Cognitive Aging Bet

In 1997, a Japanese biochemist named Makoto Kuro-o was studying mice with a strange and devastating mutation. The animals aged at terrifying speed. By eight weeks they were arthritic, infertile, vascularly calcified, cognitively dim, and dead. Kuro-o traced the cause to a single gene, then gave it a poetic name from Greek mythology. He called it Klotho, after the Fate who spins the thread of human life.

Presented By Our Partners

Almost three decades later, that thread is being pulled into a UCSF clinical trial. For the first time in history, a synthetic version of the klotho protein is being injected into healthy older adults to see whether it can sharpen memory and slow cognitive aging in humans. If the data look anything like what the same molecule has done in mice and aged rhesus monkeys, it will be one of the most consequential longevity science readouts of the decade.

This is the story of the protein your body already makes, the woman who has spent twenty years chasing it, and the 2026 trial that could decide whether klotho becomes the first true cognitive aging therapeutic.

A Molecule Hiding in Plain Sight

Klotho is not exotic. It is a 130 kilodalton transmembrane protein produced mainly in the kidney and the choroid plexus of the brain, with smaller contributions from the parathyroid and reproductive tissues. A cleaved soluble form circulates through the blood. Klotho levels peak in childhood, plateau into early adulthood, then fall steadily. By the seventh decade of life, most people have roughly half the circulating klotho they carried at twenty.

That decline tracks something. In population studies klotho concentration predicts all cause mortality, frailty trajectory, and cognitive performance independent of conventional risk factors. A 2023 review in Ageing Research Reviews pooled 65 human studies and confirmed a consistent inverse relationship between serum klotho and biological age as measured by DNA methylation clocks such as DNAm PhenoAge and GrimAge.

The reverse direction is even more striking. When researchers overexpress klotho genetically in mice, the animals live 20 to 30 percent longer. They develop fewer cancers, retain bone density, show less vascular calcification, and perform better on memory tasks well into old age. A small subset of humans carry a natural genetic variant called KL-VS that elevates circulating klotho. Heterozygous carriers, who make up roughly one in five people of European ancestry, show measurable cognitive advantages and a slower rate of brain atrophy in midlife and older age. A 2025 study in Alzheimer’s Research and Therapy reported that KL-VS heterozygosity was associated with reduced neuroinflammation and preserved synaptic markers in cognitively unimpaired older adults.

In other words, klotho looks like nature’s running gradient on cognitive resilience. The question that has occupied UCSF neurologist Dena Dubal for two decades is whether you can shift a person’s place on that gradient by giving them more of the protein.

The Twenty Year Climb to a Trial

Dubal directs the Laboratory of Neuroscience and Aging at UCSF and holds the David A. Coulter Endowed Chair in Aging and Neurodegenerative Disease. Her path to a human trial reads less like a single breakthrough and more like a careful, almost meditative climb across model systems, with each step demanding tighter mechanistic evidence than the last.

The first big result arrived in 2014. Dubal’s group showed that elevating klotho in young, middle aged, and old mice rapidly improved learning and memory. The effect appeared within hours of a single injection and lasted weeks. Importantly, the protein did not need to cross the blood brain barrier. Klotho was acting from the periphery, sending signals into the brain through a chain of intermediaries.

The 2017 follow up in Cell Reports refined the picture. Peripheral elevation of a klotho fragment enhanced brain function not only in healthy aging mice but also in transgenic animals modeling alpha synuclein pathology, the misfolded protein that drives Parkinson’s disease and Lewy body dementia. The cognitive benefits arrived without changing the underlying disease burden. Klotho appeared to confer resilience rather than cure.

Mechanistically, the lab traced klotho’s cognitive effect to a specific receptor subunit at glutamatergic synapses. NMDA receptors carrying the GluN2B subunit are central to long term potentiation, the cellular substrate of memory formation. Klotho elevation increased GluN2B at synapses, raising the gain on plasticity. Block GluN2B pharmacologically, and klotho’s memory benefit disappears.

Then came the moment the field had been waiting for. In 2023, Stacy Castner, Dubal, and collaborators published "Longevity factor klotho enhances cognition in aged nonhuman primates" in Nature Aging. A single low dose subcutaneous injection of klotho improved working memory and spatial memory in aged rhesus macaques on tasks that map cleanly onto human cognitive tests. Crucially, the effective dose was smaller than what had worked in mice, suggesting that primate brains may be more, not less, responsive to the molecule.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

That paper changed the math. Primates share 93 percent of their genome with humans, and their prefrontal cortex executes the same kinds of working memory operations that decline with human aging and early Alzheimer’s disease. A drug that worked in monkeys at low subcutaneous doses was a drug that could responsibly enter human trials.

Inside the 2026 Phase 1

The Phase 1 trial that opened in early 2025 and is now actively dosing in 2026 is, by design, deliberately modest. It is a single ascending dose study in healthy older adults, evaluating safety, pharmacokinetics, and a panel of cognitive endpoints over a 90 day window after a single subcutaneous injection. The cognitive endpoints include digit span, paired associates learning, and tasks built on the primate working memory protocols.

A trial like this does not aim to prove efficacy. It exists to answer three questions. First, is exogenous klotho safe at doses likely to be biologically active. Second, does it produce measurable target engagement, meaning detectable signals downstream in pathways like FGF23 and synaptic plasticity proxies. Third, are there any hints of cognitive change in a healthy older population, ideally in the same domains that improved in monkeys.

If the answers run favorably, Dubal has signaled that a Phase 2 trial could begin as early as 2027, with that study likely targeting specific cognitive populations such as people with mild cognitive impairment or early Parkinson’s disease cognitive decline. A 2026 paper in the Journal of Neuroscience reported that the KL-VS variant was associated with better executive cognition across two independent Parkinson’s cohorts, strengthening the case that klotho’s protective signal is specifically relevant to neurodegenerative disease, not just generic aging.

What Klotho Actually Does

The most counterintuitive part of klotho biology is that the protein does not appear to enter the brain at meaningful concentrations. Peripheral injections improve cognition within hours, far too fast for systemic remodeling, and slow enough to suggest a relay through circulating mediators. The current best model is that klotho elevates FGF23 signaling in brain regions critical for cognition, including the hippocampus and the prefrontal cortex, through a messenger pathway that has not been fully mapped.

Whatever the messenger, the downstream effect at the synapse is clear. Klotho raises the abundance of GluN2B containing NMDA receptors, the receptor variant most associated with synaptic plasticity and learning. It also influences mitochondrial function in neurons, dampens neuroinflammation, and modulates oxidative stress through interactions with insulin like growth factor 1 signaling. These are not separate stories. They are converging features of a single resilience program.

There is a kidney angle too. Klotho is the obligate co receptor for FGF23, the hormone that governs phosphate balance. Loss of klotho in the kidneys drives the vascular calcification and accelerated aging seen in chronic kidney disease patients, who carry some of the lowest klotho levels measured in adults. Several groups, including teams in Boston and Barcelona, are now studying whether klotho replacement could slow vascular aging in CKD as a parallel indication.

The Pipeline Behind the Headline

Dubal’s UCSF trial is the most prominent klotho program, but it is not the only one. A small company called Klotho Neurosciences is advancing KLTO-202, an RNA splice variant of klotho intended for ALS, with reported clinical trials targeted for late 2026. Their pipeline also includes KLTO-101, an earlier stage program for Parkinson’s and Huntington’s disease. A separate venture called Jocasta Neuroscience raised 35 million dollars in 2025 to advance klotho based therapies for cognitive impairment, building on licensed technology and additional intellectual property from academic collaborators.

Gene therapy approaches are also moving forward. Because endogenous klotho production declines with age, several preclinical programs are pursuing one time AAV based delivery of klotho to skeletal muscle or liver, with the goal of producing sustained circulating protein for years from a single administration. None of these gene therapy programs are yet in humans for cognition, but at least one is targeting a 2026 IND filing.

The competitive activity matters because it shifts the question from "will klotho ever be a drug" to "which klotho program will read out first." That is the kind of competitive density that brought CGRP migraine drugs and GLP-1 agonists from interesting biology to clinical reality within a decade once the science crossed a threshold.

The Lifestyle Side of the Equation

While the trials run, there is a parallel and underappreciated body of work on what you can do to nudge your own klotho levels. The data are not as clean as drug trials, but the signal is consistent.

Regular moderate aerobic exercise raises circulating klotho. A 2023 meta analysis published in Lifestyle Genomics found that endurance training programs of eight to twelve weeks measurably elevated serum klotho in middle aged and older adults. Resistance training contributes as well, though the effect appears smaller. Overtraining, however, reverses these benefits, which fits klotho’s role as a stress response modulator rather than a generic anabolic signal.

Diet matters at the margins. Vitamin D sufficiency is consistently associated with higher klotho levels in observational studies. Mediterranean style diets, polyphenol rich foods, and adequate plant protein appear protective. Chronic high glucose, smoking, and chronic kidney disease all suppress klotho.

Sleep regularity, which we have covered separately, is an emerging contributor. Cohort data link consistent circadian alignment with higher serum klotho, though causality has not been established. The mechanistic plausibility is straightforward. Klotho production responds to circadian transcription factors in both the kidney and the brain.

None of these lifestyle moves will replicate a clinical dose of klotho. They will, however, slow the decline. And given how dramatically klotho falls with age in most people, slowing the slope is a meaningful goal in itself.

Why This Trial Matters Beyond Klotho

The klotho story is interesting in its own right. It is also a template. For two decades the longevity field has been waiting for a molecule that meets three criteria. It must have a clear biological role in healthy aging that is conserved across species. It must produce reproducible cognitive benefits in non human primates, the gold standard short of humans. And it must have a plausible therapeutic window, meaning a dose at which biological effect emerges without unmanageable risk.

Klotho is the cleanest molecule in the field that meets all three. If the Phase 1 reads out safely and shows even modest signals of target engagement, it will accelerate investment in the entire class of resilience proteins, including FGF21, GDF11, and humanin. If the Phase 2 in cognitively at risk populations shows a benefit, the regulatory and commercial landscape for cognitive aging changes overnight.

If both fail, the field will absorb the lesson that translation from primates to humans is harder than it looks, and the resilience program will shift to the next candidate. Either way, the data due in late 2026 and 2027 will tell the longevity field where it really stands.

What This Means For You

There is no klotho therapy you can take today. The Phase 1 trial is enrolling a small number of carefully selected healthy older adults at UCSF, and the protein is not available outside that protocol. Be wary of any clinic or supplement marketing klotho as a treatment. Most products marketed under that name are unrelated to the actual protein.

What you can do is treat klotho as a useful frame for the lifestyle work that already has strong evidence. Regular moderate aerobic exercise of 150 minutes a week, complemented by resistance training, raises measured serum klotho in older adults. Vitamin D sufficiency, generally a serum level above 30 ng per mL, is associated with higher klotho. A Mediterranean style diet, adequate sleep regularity, and avoidance of chronic glycemic excursions all support the same biology. Each of these moves has independent evidence for cognitive aging benefit. Klotho gives you a single biomarker that captures much of what they are doing.

If you have a family history of early cognitive decline, or you are tracking your own biological age through DNA methylation testing, klotho is worth asking your physician about. Several specialty labs now offer serum klotho assays, and while reference ranges are still being refined, the test is reproducible enough to track over time. Watching your klotho move with your training, your diet, and your sleep is a more grounded use of the protein today than waiting for a drug.

The clinical readout to watch is the UCSF Phase 1, with topline safety and pharmacokinetic data expected in 2027. If that trial moves cleanly into a Phase 2 in mild cognitive impairment or early Parkinson’s, klotho will move from interesting biology to a real prospect for the cognitive aging therapeutics that geriatric medicine has lacked for a generation. The thread that Makoto Kuro-o named in 1997 may yet prove longer than anyone expected.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.